🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Addus HomeCare Corporation ADUS R2K

Healthcare · Medical Care Facilities · United States
https://www.addus.com
Company Profile ↓
$110.17
-1.41% 1Y
Mkt Cap$2.06B
P/E20.33
P/B1.53
52W High$122.75
52W Low$88.49
Book Value$61.05
EPS (TTM)$5.42

Company Overview

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 27.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 20.3, below the sector median of 25.9.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.12.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.42B (+23.2% YoY); net profit $95.91M.
  • Trailing 12 Months Year-on-year growth — revenue +7.7%, earnings +17.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.4%, profit CAGR 27.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.36%
1 Year:7.70%

Compounded Profit Growth

5 Years:27.73%
1 Year:17.20%

Stock Price Performance

1 Year:-1.41%
6 Months:-1.11%
3 Months:+18.17%
1 Month:+18.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 63% of range
$88.49 $122.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)77.85 · Overbought
Price Performance
1M+18.11%
3M+18.17%
6M-1.11%
1Y-1.41%
Valuation vs Sector

P/E of 20.33 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 14.4% over 5 years.
  • Profit CAGR of 27.7% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 78 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.33
Industry PE
25.88
Forward P/E
14.74
PEG Ratio
0.90
Book Value
$61.05
Price to Book
1.53
P/S
1.20
EV/EBITDA
10.89
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.36%
Profit 5Y
27.73%
Revenue (YoY)
7.70%
Earnings (YoY)
17.20%

Profitability & Returns

ROCE
10.95%
ROE
9.45%
ROA
6.30%
Profit Margin
6.89%
Op Margin
9.37%
Gross Margin
32.45%
EPS (Latest Qtr)
$1.34
EPS (TTM)
$5.42

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
1.68
Current Ratio
1.83
Debt
$138.74M
Total Assets
$1.44B
Current Assets
$272.88M
Working Capital
$120.00M

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$2.06B
Total Revenue (TTM)
$1.45B
EBITDA
$159.87M
Free Cash Flow
$102.89M
Operating Cash Flow
$144.92M
Shares Outstanding
18.66M
Gross Margin
32.45%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADUS Addus HomeCare Corporation R2K 110.17 20.33 $2.06B 0.00% 10.95% 9.45% 14.36% 27.73%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------101.67M103.63M108.66M112.03M109.13M130.89M137.34M139.29M138.51M148.91M168.99M192.38M190.22M184.58M193.99M196.00M205.30M217.89M216.66M226.63M236.94M240.50M251.60M259.98M270.72M280.75M286.92M289.79M337.71M349.44M362.30M373.08M363.61M
Cost of Revenue -----------------------------------230.03M235.57M245.59M249.47M247.74M
Gross Profit 23.68M23.52M22.19M24.32M25.70M27.42M28.66M27.39M28.58M29.12M30.79M27.58M35.38M36.41M37.43M36.83M39.69M45.18M57.54M55.84M55.00M56.30M59.10M61.20M68.81M67.05M70.19M75.60M75.19M78.42M82.32M86.73M88.18M93.16M92.20M107.68M113.88M116.72M123.61M115.87M
Operating Expenses -----------------------------------77.16M80.99M83.78M81.33M81.80M
Operating Income 5.10M4.28M3.02M653.00K4.39M2.50M7.69M7.03M5.99M5.88M7.47M4.24M6.55M5.61M6.43M5.50M7.39M7.33M14.53M10.66M9.61M12.52M11.72M12.17M17.05M17.36M13.51M16.89M17.52M18.61M21.54M22.84M23.64M26.18M25.95M30.51M32.89M32.94M42.28M34.07M
EBITDA -----------------------------------34.96M37.38M38.10M47.02M38.61M
Interest Expense -----------------------------------4.02M3.52M3.34M2.73M2.15M
Pretax Income -----------------------------------27.00M29.95M30.35M40.15M32.43M
Tax Provision -----------------------------------5.77M7.89M7.51M10.37M7.36M
Net Income 3.25M2.89M3.32M157.00K2.60M1.70M7.57M4.31M2.76M3.46M3.15M4.63M4.05M3.36M4.39M4.30M5.29M4.91M10.74M8.66M6.91M9.12M8.45M8.89M11.60M11.58M8.47M11.25M11.54M12.68M14.85M15.41M15.83M18.08M20.16M21.23M22.05M22.85M29.78M25.07M
Diluted EPS 0.290.260.290.010.230.150.660.370.240.290.270.400.340.270.330.320.390.350.680.540.430.570.530.550.720.720.530.700.710.780.910.950.971.101.101.151.201.241.611.34

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------400.93M425.99M516.65M648.79M764.77M-951.12M1.06B1.15B1.42B
Cost of Revenue -------------651.38M718.77M779.58M960.66M
Gross Profit 76.61M59.72M61.47M64.05M67.74M83.73M91.32M106.34M115.88M136.80M179.24M226.24M-299.74M339.88M375.02M461.87M
Operating Expenses -------------231.00M248.92M272.33M323.26M
Operating Income 11.78M9.27M12.92M15.66M15.46M18.07M16.02M15.48M25.25M22.83M34.75M44.51M-68.74M90.96M102.69M138.62M
EBITDA -------------83.14M106.56M120.61M157.47M
Interest Expense -------------8.91M11.11M7.73M13.61M
Pretax Income -------------60.17M81.33M99.35M127.44M
Tax Provision -------------14.15M18.81M25.75M31.54M
Net Income 3.60M6.03M-1.98M7.63M19.14M12.24M11.62M12.16M11.95M16.43M25.24M33.13M-46.02M62.52M73.60M95.91M
Diluted EPS ---0.180.711.731.101.041.071.031.331.772.08-2.843.834.065.18

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --166.92M154.69M149.86M163.93M180.80M185.80M229.86M271.69M348.09M636.75M892.58M-937.99M1.02B1.41B1.44B
Current Assets --------------222.81M200.00M260.38M269.49M
Cash & Equivalents 6.11M518.00K816.00K2.02M1.74M15.56M13.36M4.10M8.01M53.75M70.41M111.71M145.08M-79.96M64.79M98.91M81.62M
Inventory ------------------
Receivables --------------125.50M115.50M122.88M151.69M
Total Liabilities --78.83M68.25M55.44M50.08M52.85M44.07M72.10M95.38M79.60M161.16M373.91M-304.45M317.73M442.14M352.00M
Current Liabilities --37.13M43.29M39.19M45.54M43.20M42.19M49.62M55.08M61.50M87.53M143.90M-131.15M145.12M155.87M149.49M
Long Term Debt --40.03M24.96M16.25M--1.88M22.48M39.86M17.22M59.16M193.90M-131.77M124.13M218.44M120.96M
Total Debt --------------178.05M175.18M273.13M171.36M
Total Equity 34.58M80.57M88.09M86.44M94.42M113.86M126.79M141.58M154.67M170.34M268.49M475.59M518.68M-633.54M706.69M970.49M1.09B
Shares Outstanding --------------16.13M16.23M18.15M18.52M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.93M10.70M15.95M15.40M27.39M-4.11M-743.00K52.77M33.20M12.02M109.41M-105.11M112.25M116.43M111.51M
Investing Cash Flow -14.85M-6.20M-1.05M-619.00K2.89M--10.72M-21.74M-24.27M-67.79M-188.70M-214.24M--106.59M-119.24M-354.61M-32.50M
Financing Cash Flow 18.18M-4.21M-13.69M-15.07M-16.46M--2.64M26.39M17.24M51.24M217.99M138.19M--87.45M-8.18M272.30M-96.30M
Capital Expenditure -671.00K-612.00K-551.00K-1.11M-887.00K-5.27M-2.21M-1.71M-3.62M-5.35M-4.62M-6.83M--8.30M-9.45M-6.05M-7.72M
Free Cash Flow -9.60M10.09M15.40M14.29M26.51M-1.89M-2.46M49.16M27.85M7.40M102.58M-96.81M102.79M110.38M103.79M
Net Change in Cash --------------88.93M-15.17M34.12M-17.29M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------26.5%27.2%26.5%27.6%29.6%-31.5%32.1%32.5%32.5%
Operating Margin % -------3.9%5.9%4.4%5.4%5.8%-7.2%8.6%8.9%9.7%
Net Margin % -------3.0%2.8%3.2%3.9%4.3%-4.8%5.9%6.4%6.7%
ROE % 4.5%6.8%-2.3%8.1%16.8%9.7%8.2%7.9%7.0%6.1%5.3%6.4%-7.3%8.8%7.6%8.8%
ROCE % -7.1%11.6%14.2%13.1%13.1%11.2%8.6%11.7%8.0%6.3%5.9%-8.5%10.3%8.2%10.8%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADUS

Yahoo Finance Wed, 15 Jul 2026

Is Addus HomeCare (ADUS) One of the Best Small Cap Stocks to Buy With the Highest Upside Potential?

Addus HomeCare Corporation (NASDAQ:ADUS) is one of the best small cap stocks to buy with the highest upside potential. Barclays lifted the price target on Addus HomeCare Corporation (NASDAQ:ADUS) to $96 from $92 on July 8 and maintained an …

Yahoo Finance Mon, 06 Jul 2026

Q1 Earnings Highs And Lows: Addus HomeCare (NASDAQ:ADUS) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how senior health, home health & hospice stocks fared in Q1, starting with Addus HomeCare (NASDAQ:ADUS).…

Yahoo Finance hu, 25 Jun 2026

3 of Wall Street’s Favorite Stocks That Fall Short

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about comp…

Yahoo Finance Fri, 12 Jun 2026

3 Healthcare Stocks with Open Questions

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 6.4% over the past si…

Yahoo Finance Mon, 01 Jun 2026

1 Value Stock Worth Your Attention and 2 Facing Challenges

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents…

Yahoo Finance Mon, 25 May 2026

Assessing Addus HomeCare (ADUS) Valuation After Recent Share Price Weakness

Why Addus HomeCare Stock Is Back on Investors’ Radar Addus HomeCare (ADUS) has drawn fresh attention after a year in which the stock declined about 17% and is down about 13% year to date, despite reported revenue and net income growth. See …

ADUS — Frequently Asked Questions

What is the current share price of Addus HomeCare Corporation (ADUS)?

As of 2026-07-15 16:51 PDT, Addus HomeCare Corporation (ADUS) trades at $110.17 on NasdaqGS. Its 52-week range is $88.49 to $122.75.

What is the market capitalisation of ADUS?

Addus HomeCare Corporation (ADUS) has a market capitalisation of $2.06B on NasdaqGS.

What is the P/E ratio of ADUS?

ADUS trades at a trailing price-to-earnings (P/E) ratio of 20.33. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.53.

What is the return on equity (ROE) of ADUS?

ADUS has a return on equity (ROE) of 9.45%. Its return on capital employed (ROCE) is 10.95%.

Is ADUS a good stock to buy?

This page provides a data-driven analysis of Addus HomeCare Corporation (ADUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space